Webinar
Contents
Introduction
MASH/MASLD incidence rates are continuing to rise globally year after year as the disease continues to be a global health concern. Although no pharmaceutical drugs have yet received regulatory approval, there are a number of therapeutics in late-phase clinical trials, case studies of which will be discussed at the congress, as well as pre-clinical developments. Potential alternatives for MASH diagnosis in the form of non-invasive biomarkers will be explored to replace the invasive liver biopsy. Advances in the research of MASH disease mechanisms such as genetic predisposition, gut microbiome, and mitochondrial dysfunction will be covered as the disease pathology continues to be complex and not fully understood.
Time and Venue: 24-25 June 2024 | The London Heathrow Marriot Hotel
Register: https://global-engage.com/product/global-masld-2024/
Time and Venue: 24-25 June 2024 | The London Heathrow Marriot Hotel
Register: https://global-engage.com/product/global-masld-2024/